ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > prospectus details on use of funds raised recently

<< Previous

Bullboard Posts

Next >>

Comment by Speyeder999on Dec 06, 2020 11:44pm

196 Views

Post# 32047543

RE:prospectus details on use of funds raised recently

Interesting. Thanks Gbathat.And what I also noticed on page 21 is they mention a timing for these objectives and Milestones: Business Objectives and Milestones The following is a summary of the Companys business objectives and the milestones associated with attaining those objectives. Expand the ProMIS therapeutic portfolio(2) $459,156 Q1 2021 Neurodegenerative disease diagnostics (AD diagnostics)(3) $228,100 Q1 2021 Alzheimers disease therapeutic vaccine(4) $123,000 Q2 2021 Am I reading this correctly? They actually plan on rolling out something before the end of March?

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market